Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

Current landscape of treatment of castration-resistant prostate cancer (CRPC) has recently changed. Cabazitaxel, a new taxane with potential antineoplastic activity, has been approved by Food and Drug Administration (FDA) after docetaxel failure. In a phase III trial, cabazitaxel showed increased ov...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Altavilla, Amelia, Iacovelli, Roberto, Procopio, Giuseppe, Alesini, Daniele, Risi, Emanuela, Campennì, Giuseppe Maria, Palazzo, Antonella, Cortesi, Enrico
Format: Artigo
Jezik:Inglês
Izdano: Landes Bioscience 2012
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461806/
https://ncbi.nlm.nih.gov/pubmed/22825325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.21188
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki